AZN—Imfinzi/Tremelimumab combo not better than chemo in third-line NSCLC in patients with low (or zero) PD-L1 expression (sub-study ‘B’ of ARCTIC phase-3 trial):
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.